APA (7th ed.) Citation

Federico, A., Steinfass, T., Larribere, L., Novak, D., Morís, F., Núñez, L., . . . Utikal, J. (2020). Mithramycin A and Mithralog EC-8042 inhibit SETDB1 expression and its oncogenic activity in malignant melanoma. Molecular therapy. Oncolytics, 18, . https://doi.org/10.1016/j.omto.2020.06.001

Chicago Style (17th ed.) Citation

Federico, Aniello, Tamara Steinfass, Lionel Larribere, Daniel Novak, Francisco Morís, Luz-Elena Núñez, Viktor Umansky, and Jochen Utikal. "Mithramycin A and Mithralog EC-8042 Inhibit SETDB1 Expression and Its Oncogenic Activity in Malignant Melanoma." Molecular Therapy. Oncolytics 18 (2020). https://doi.org/10.1016/j.omto.2020.06.001.

MLA (9th ed.) Citation

Federico, Aniello, et al. "Mithramycin A and Mithralog EC-8042 Inhibit SETDB1 Expression and Its Oncogenic Activity in Malignant Melanoma." Molecular Therapy. Oncolytics, vol. 18, 2020, https://doi.org/10.1016/j.omto.2020.06.001.